Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics Previous close 1.3060
Open 1.3090
Day range 1.2730 1.3090
52-week range 1.2500 6.5900
Off day high −1.30%
Off 52-week high −80.39%
Volume 129.02K
Avg. volume (3M) 1.26M
Market cap 364.27M
EPS (TTM) 0.6800
Forward P/E -1.37
P/E ratio (TTM) 1.90
Dividend yield —
Beta (5Y) 1.56
Shares outstanding 281.94M
Short interest —
Earnings date Nov 25, 2026
Analyst target 8.2500
Profit margin 52.75%
No recent coverage in the 4Search index.
From articles in the 4Search news index.
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sc…
Sector Healthcare
Industry Biotechnology
Chief executive Hilde Hermansen Steineger M.Sc., MSc, Ph.D.
Employees 22
Headquarters Lund, Sweden
— 1 analysts
0 1 0 0 0 12-month price target 8.2500 +538.54%
Low 4.5000 Current 1.2920 High 12.0000
Wall Street analyst consensus. Not a recommendation.
Earnings
Next report: Wed, Nov 25, 2026
Net margin −34,548.4% (Q2 '26) Prices may be delayed up to 15 min. Not investment advice.
Not eligible for Gainers, Losers, Most active (U.S. stocks worth $2 billion or more only).
Not eligible for Small-cap gainers, Aggressive small caps (U.S. stocks worth under $2 billion only).
Not eligible for Growth tech (U.S. technology stocks only).
Not eligible for Undervalued large caps (U.S. stocks worth $10 billion or more only).
A day counts when it ranked in the top 25 of a list. Tracked since Oct 10, 2026.
Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use .